| Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non … KK Jørgensen, IC Olsen, GL Goll, M Lorentzen, N Bolstad, ... The Lancet 389 (10086), 2304-2316, 2017 | 914 | 2017 |
| Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients KK Jφrgensen, K Grzyb, KEA Lundin, OPF Clausen, G Aamodt, ... Inflammatory bowel diseases 18 (3), 536-545, 2012 | 148 | 2012 |
| Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study I Jyssum, H Kared, TT Tran, AT Tveter, SA Provan, J Sexton, ... The Lancet Rheumatology 4 (3), e177-e187, 2022 | 140 | 2022 |
| Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial GL Goll, KK Jørgensen, J Sexton, IC Olsen, N Bolstad, EA Haavardsholm, ... Journal of internal medicine 285 (6), 653-669, 2019 | 116 | 2019 |
| Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a … SW Syversen, GL Goll, KK Jørgensen, Ø Sandanger, J Sexton, IC Olsen, ... Jama 325 (17), 1744-1754, 2021 | 113 | 2021 |
| Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a … SW Syversen, KK Jørgensen, GL Goll, MK Brun, Ø Sandanger, ... Jama 326 (23), 2375-2384, 2021 | 106 | 2021 |
| A cross-sectional study of the prevalence of gastrointestinal symptoms and pathology in patients with common variable immunodeficiency SF Jørgensen, HM Reims, D Frydenlund, K Holm, V Paulsen, ... Official journal of the American College of Gastroenterology| ACG 111 (10 …, 2016 | 100 | 2016 |
| Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis D Kevans, AD Tyler, K Holm, KK Jørgensen, MH Vatn, TH Karlsen, ... Journal of Crohn's and Colitis 10 (3), 330-337, 2016 | 88 | 2016 |
| Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study L Lindström, KK Jørgensen, KM Boberg, M Castedal, A Rasmussen, ... Scandinavian journal of gastroenterology 53 (3), 297-304, 2018 | 81 | 2018 |
| Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease KK Jørgensen, L Lindström, M Cvancarova, TH Karlsen, M Castedal, ... Clinical Gastroenterology and Hepatology 11 (5), 517-523, 2013 | 74 | 2013 |
| Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study KK Jørgensen, L Lindström, M Cvancarova, M Castedal, S Friman, ... Scandinavian journal of gastroenterology 47 (8-9), 1021-1029, 2012 | 66 | 2012 |
| Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease EKK Henriksen, KK Jørgensen, F Kaveh, K Holm, D Hamm, J Olweus, ... Journal of hepatology 66 (1), 116-122, 2017 | 65 | 2017 |
| Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy SW Syversen, I Jyssum, AT Tveter, TT Tran, J Sexton, SA Provan, ... Arthritis & Rheumatology 74 (8), 1321-1332, 2022 | 44 | 2022 |
| Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis NH Nguyen, V Solitano, SK Vuyyuru, JK MacDonald, SW Syversen, ... Gastroenterology 163 (4), 937-949. e2, 2022 | 35 | 2022 |
| Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV … SW Syversen, GL Goll, KK Jørgensen, IC Olsen, Ø Sandanger, JE Gehin, ... Trials 21, 1-14, 2020 | 34 | 2020 |
| Paucity of mycobacteria in mucosal bowel biopsies from adults and children with early inflammatory bowel disease P Ricanek, SM Lothe, I Szpinda, AT Jorde, S Brackmann, G Perminow, ... Journal of Crohn's and Colitis 4 (5), 561-566, 2010 | 32 | 2010 |
| Experience with biosimilar infliximab (Remsima®) in Norway J Jahnsen, K Kaasen Jørgensen Digestive Diseases 35 (1-2), 83-90, 2017 | 31 | 2017 |
| Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: a retrospective study comparing chromoendoscopy and white-light endoscopy JR Ten Hove, E Mooiweer, E Dekker, CY Ponsioen, PD Siersema, ... Endoscopy 49 (02), 161-168, 2017 | 30 | 2017 |
| Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis CRH Hedin, G Sado, N Ndegwa, E Lytvyak, A Mason, A Montano-Loza, ... Clinical Gastroenterology and Hepatology 18 (10), 2295-2304. e2, 2020 | 27 | 2020 |
| Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis—what next? M Block, KK Jørgensen, T Öresland, E Lindholm, K Grzyb, M Cvancarova, ... Journal of Crohn's and Colitis 8 (5), 421-430, 2014 | 27 | 2014 |
